Targeting the Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma

He, 2015, The role of clinically significant portal hypertension in hepatic resection for hepatocellular carcinoma patients: A propensity score matching analysis, BMC Cancer, 15, 263, 10.1186/s12885-015-1280-3

Yang, 2015, Radiofrequency ablation versus percutaneous ethanol injection for hepatocellular carcinoma: A meta-analysis of randomized controlled trials, World J Surg Oncol, 13, 96, 10.1186/s12957-015-0516-7

Baek, 2012, Efficacy of hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma, World J Gastroenterol, 18, 3426, 10.3748/wjg.v18.i26.3426

Kim, 2011, Hepatocellular carcinoma with portal vein tumor thrombosis: Improved treatment outcomes with external beam radiation therapy, Hepatol Res, 41, 813, 10.1111/j.1872-034X.2011.00826.x

Buscà, 2016, ERK1 and ERK2 Map Kinases: Specific Roles or Functional Redundancy?, Front Cell Dev Biol, 4, 53, 10.3389/fcell.2016.00053

Wang, 2016, Bicyclol induces cell cycle arrest and autophagy in HepG2 human hepatocellular carcinoma cells through the PI3K/AKT and Ras/Raf/MEK/ERK pathways, BMC Cancer, 16, 742, 10.1186/s12885-016-2767-2

Asati, 2016, PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives, Eur J Med Chem, 109, 314, 10.1016/j.ejmech.2016.01.012

Lee, 2015, Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: A retrospective study of routine clinical practice in multi-institutions, BMC Cancer, 15, 236, 10.1186/s12885-015-1273-2

Yu, 2015, NSK-01105 inhibits proliferation and induces apoptosis of prostate cancer cells by blocking the Raf/MEK/ERK and PI3K/Akt/mTOR signal pathways, Tumour Biol, 36, 2143, 10.1007/s13277-014-2824-x

Huynh, 2010, AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC), J Hepatol, 52, 79, 10.1016/j.jhep.2009.10.008

Zhou, 2011, Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma, Future Oncol, 7, 1149, 10.2217/fon.11.95

Jiang, 2015, Genome-wide exploration of the molecular evolution and regulatory network of mitogen-activated protein kinase cascades upon multiple stresses in Brachypodium distachyon, BMC Genomics, 16, 228, 10.1186/s12864-015-1452-1

Ward, 2012, Targeting oncogenic Ras signaling in hematologic malignancies, Blood, 120, 3397, 10.1182/blood-2012-05-378596

Knight, 2014, Ras/Raf/MEK/ERK pathway activation in childhood acute lymphoblastic leukemia and its therapeutic targeting, Front Oncol, 4, 160, 10.3389/fonc.2014.00160

Chang, 2013, Roles of targeting Ras/Raf/MEK/ERK signaling pathways in the treatment of esophageal carcinoma, Yao Xue Xue Bao, 48, 635

Zebisch, 2006, Back to the roots: The remarkable RAF oncogene story, Cell Mol Life Sci, 63, 1314, 10.1007/s00018-006-6005-y

Moodie, 1994, The 3Rs of life: Ras, Raf and growth regulation, Trends Genet, 10, 44, 10.1016/0168-9525(94)90147-3

De Luca, 2012, The RAS/RAF/MEK/ERK and the PI3K/AKT signaling pathways: Role in cancer pathogenesis and implications for therapeutic approaches, Expert Opin Ther Targets, 16, S17, 10.1517/14728222.2011.639361

Steelman, 2011, Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy, Leukemia, 25, 1080, 10.1038/leu.2011.66

Trujillo, 2011, MEK inhibitors: A patent review 2008–2010, Expert Opin Ther Pat, 21, 1045, 10.1517/13543776.2011.577068

Chung, 2011, Role of Ras/Raf/MEK/ERK signaling in physiological hematopoiesis and leukemia development, Immunol Res, 49, 248, 10.1007/s12026-010-8187-5

Ito, 1998, Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma, Hepatology, 27, 951, 10.1002/hep.510270409

Hoffmann, 2011, Correlation of gene expression of ATP-binding cassette protein and tyrosine kinase signaling pathway in patients with hepatocellular carcinoma, Anticancer Res, 31, 3883

Zuo, 2012, Multivariate analysis of several molecular markers and clinicopathological features in postoperative prognosis of hepatocellular carcinoma, Anat Rec (Hoboken), 295, 423, 10.1002/ar.21531

Liu, 2006, Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5, Cancer Res, 66, 11851, 10.1158/0008-5472.CAN-06-1377

Gollob, 2006, Role of Raf kinase in cancer: Therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway, Semin Oncol, 33, 392, 10.1053/j.seminoncol.2006.04.002

Tang, 1998, Alterations of oncogenes, tumor suppressor genes and growth factors in hepatocellular carcinoma: With relation to tumor size and invasiveness, Chin Med J (Engl), 111, 313

Wiedmann, 2011, Molecular targeted therapy of hepatocellular carcinoma-results of the first clinical studies, Curr Cancer Drug Targets, 11, 714, 10.2174/156800911796191033

Poon, 2004, Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma, Br J Surg, 91, 1354, 10.1002/bjs.4594

Dhar, 2002, Requisite role of VEGF receptors in angiogenesis of hepatocellular carcinoma: A comparison with angiopoietin/Tie pathway, Anticancer Res, 22, 379

Tavian, 2000, u-PA and c-MET mRNA expression is co-ordinately enhanced while hepatocyte growth factor mRNA is down-regulated in human hepatocellular carcinoma, Int J Cancer, 87, 644, 10.1002/1097-0215(20000901)87:5<644::AID-IJC4>3.0.CO;2-W

Whittaker, 2010, The role of signaling pathways in the development and treatment of hepatocellular carcinoma, Oncogene, 29, 4989, 10.1038/onc.2010.236

Giambartolomei, 2001, Sustained activation of the Raf/MEK/Erk pathway in response to EGF in stable cell lines expressing the Hepatitis C Virus (HCV) core protein, Oncogene, 20, 2606, 10.1038/sj.onc.1204372

Wang, 2001, Microinjection technique used to study functional interaction between p53 and hepatitis B virus X gene in apoptosis, Mol Biotechnol, 18, 169, 10.1385/MB:18:2:169

Nakamura, 2011, HCV core protein promotes heparin binding EGF-like growth factor expression and activates Akt, Hepatol Res, 41, 455, 10.1111/j.1872-034X.2011.00792.x

Schmitz, 2008, Activation of the ERK and AKT signaling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection, J Hepatol, 48, 83, 10.1016/j.jhep.2007.08.018

Hayashi, 2000, Hepatitis C virus core protein activates the MAPK/ERK cascade synergistically with tumor promoter TPA, but not with epidermal growth factor or transforming growth factor alpha, Hepatology, 32, 958, 10.1053/jhep.2000.19343

Colombino, 2012, BRAF and PIK3CA genes are somatically mutated in hepatocellular carcinoma among patients from South Italy, Cell Death Dis, 3, e259, 10.1038/cddis.2011.136

Kalinina, 2013, Somatic changes in primary liver cancer in Russia: A pilot study, Mutat Res, 755, 90, 10.1016/j.mrgentox.2013.06.019

Challen, 1992, Infrequent point mutations in codons 12 and 61 of ras oncogenes in human hepatocellular carcinomas, J Hepatol, 14, 342, 10.1016/0168-8278(92)90181-N

Saini, 2013, Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer, Cancer Treat Rev, 39, 935, 10.1016/j.ctrv.2013.03.009

Taketomi, 2013, A rare point mutation in the Ras oncogene in hepatocellular carcinoma, Surg Today, 43, 289, 10.1007/s00595-012-0462-8

Marom, 1995, Selective inhibition of Ras-dependent cell growth by farnesylthiosalisylic acid, J Biol Chem, 270, 22263, 10.1074/jbc.270.38.22263

Haklai, 1998, Dislodgment and accelerated degradation of Ras, Biochemistry, 37, 1306, 10.1021/bi972032d

McMahon, 2005, Farnesylthiosalicylic acid inhibits mammalian target of rapamycin (mTOR) activity both in cells and in vitro by promoting dissociation of the mTOR-raptor complex, Mol Endocrinol, 19, 175, 10.1210/me.2004-0305

Blum, 2007, Gene expression signature of human cancer cell lines treated with the ras inhibitor salirasib (S-farnesylthiosalicylic acid), Cancer Res, 67, 3320, 10.1158/0008-5472.CAN-06-4287

Tsimberidou, 2010, Phase 1 first-in-human clinical study of S-trans, trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors, Cancer Chemother Pharmacol, 65, 235, 10.1007/s00280-009-1027-4

Charette, 2010, Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition, Mol Cancer, 9, 256, 10.1186/1476-4598-9-256

da Silva Morais, 2008, Inhibition of the Ras oncoprotein reduces proliferation of hepatocytes in vitro and in vivo in rats, Clin Sci (Lond), 114, 73, 10.1042/CS20070152

Schneider-Merck, 2009, The Ras inhibitor farnesylthiosalicyclic acid (FTS) prevents nodule formation and development of preneoplastic foci of altered hepatocytes in rats, Eur J Cancer, 45, 2050, 10.1016/j.ejca.2009.04.014

Wecksler, 2015, Biological evaluation of a novel sorafenib analogue, t-CUPM, Cancer Chemother Pharmacol, 75, 161, 10.1007/s00280-014-2626-2

Fucile, 2015, Measurement of sorafenib plasma concentration by high-performance liquid chromatography in patients with advanced hepatocellular carcinoma: Is it useful the application in clinical practice? A pilot study, Med Oncol, 32, 335, 10.1007/s12032-014-0335-7

Guan, 2011, Sorafenib: Activity and clinical application in patients with hepatocellular carcinoma, Expert Opin Pharmacother, 12, 303, 10.1517/14656566.2011.546346

Arrondeau, 2012, Sorafenib exposure decreases over time in patients with hepatocellular carcinoma, Invest New Drugs, 30, 2046, 10.1007/s10637-011-9764-8

Peng, 2014, An updated meta-analysis of randomized controlled trials assessing the effect of sorafenib in advanced hepatocellular carcinoma, PLoS One, 9, e112530, 10.1371/journal.pone.0112530

Sathornsumetee, 2006, AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant glioma, Cancer Res, 66, 8722, 10.1158/0008-5472.CAN-06-0284

Lang, 2008, Dual targeting of Raf and VEGF receptor 2 reduces growth and metastasis of pancreatic cancer through direct effects on tumor cells, endothelial cells, and pericytes, Mol Cancer Ther, 7, 3509, 10.1158/1535-7163.MCT-08-0373

Lang, 2008, Dual inhibition of Raf and VEGFR2 reduces growth and vascularization of hepatocellular carcinoma in an experimental model, Langenbecks Arch Surg, 393, 333, 10.1007/s00423-008-0292-8

Cotrim, 2011, Estrogenic effect of the MEK1 inhibitor PD98059 on endogenous estrogen receptor alpha and beta, J Steroid Biochem Mol Biol, 124, 25, 10.1016/j.jsbmb.2010.12.020

Han, 2016, Leptin induces osteocalcin expression in ATDC5 cells through activation of the MAPK-ERK1/2 signaling pathway, Oncotarget, 10.18632/oncotarget.11578

Davis, 2016, ARF1 promotes prostate tumorigenesis via targeting oncogenic MAPK signaling, Oncotarget, 7, 39834, 10.18632/oncotarget.9405

Montagut, 2009, Targeting the RAF-MEK-ERK pathway in cancer therapy, Cancer Lett, 283, 125, 10.1016/j.canlet.2009.01.022

Barrett, 2008, The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901, Bioorg Med Chem Lett, 18, 6501, 10.1016/j.bmcl.2008.10.054

Lorusso, 2005, Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies, J Clin Oncol, 23, 5281, 10.1200/JCO.2005.14.415

Rinehart, 2004, Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer, J Clin Oncol, 22, 4456, 10.1200/JCO.2004.01.185

Ciuffreda, 2009, Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations, Neoplasia, 11, 720, 10.1593/neo.09398

Lorusso, 2010, Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers, Clin Cancer Res, 16, 1924, 10.1158/1078-0432.CCR-09-1883

Haura, 2010, A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer, Clin Cancer Res, 16, 2450, 10.1158/1078-0432.CCR-09-1920

Davies, 2007, AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: Mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models, Mol Cancer Ther, 6, 2209, 10.1158/1535-7163.MCT-07-0231

Do, 2015, Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer, Invest New Drugs, 33, 720, 10.1007/s10637-015-0212-z

Grasso, 2016, Autophagy regulates Selumetinib (AZD6244) induced-apoptosis in colorectal cancer cells, Eur J Med Chem, 122, 611, 10.1016/j.ejmech.2016.06.043

Yang, 2016, Selumetinib attenuate skeletal muscle wasting in murine cachexia model through ERK inhibition and AKT activation, Mol Cancer Ther

O'Neil, 2011, Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma, J Clin Oncol, 29, 2350, 10.1200/JCO.2010.33.9432

Holkova, 2016, Phase II trial of AZD6244 (Selumetinib, ARRY-142886), an oral MEK1/2 inhibitor, in relapsed/refractory multiple myeloma, Clin Cancer Res, 22, 1067, 10.1158/1078-0432.CCR-15-1076

Coleman, 2015, A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study, Gynecol Oncol, 138, 30, 10.1016/j.ygyno.2015.04.005

Barrett, 2008, The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901, Bioorg Med Chem Lett, 18, 6501, 10.1016/j.bmcl.2008.10.054